Program
Friday, March 13
Saturday, March 14
- Plenary Session 1: Immunotherapy in Kidney Cancer
- Plenary Session 2: Targeting Tumor Metabolism in Kidney Cancer
- Plenary Session 3: New Paradigms on Kidney Cancer Treatments
SUNDAY, March 15
- Plenary Session 4: Modeling Kidney Cancer
- Plenary Session 5: Tumor Evolutions, Chromosomal Instability and Metastatic Tissue Tropism in Kidney Cancer
- Plenary Session 6: Advances on Studying Oncogenes and Tumor Suppressors in Kidney Cancer
Monday, March 16
- Plenary Session 7: Subtypes of Kidney Cancer and Therapeutic Implications
- Plenary Session 8 : Targeting Epigenetics in Kidney Cancer
- Closing Remarks
Friday, March 13
WELCOME AND OPENING Keynote
5:30-7:30 p.m.
- 5:30 p.m. | Keynote Lecture
Carl H. June, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania - 6:30 p.m. | Keynote Lecture
William G. Kaelin, Dana-Farber Cancer Institute, Boston, Massachusetts
OPENING RECEPTION
7:30-9 p.m.
Saturday, March 14
CONTINENTAL BREAKFAST
7-8 a.m.
Plenary Session 1: Immunotherapy in Kidney Cancer
8-10 a.m.
- 8 a.m. | Metabolic mechanisms controlling T cell immunity to kidney cancer
Haydn Kissick, Emory University, Atlanta, Georgia - 8:30 a.m. | Defining the determinants of anti-tumor immunity in renal cell carcinoma
David A. Braun, Yale School of Medicine, New Haven, Connecticut - 9 a.m. | ERVs, epigenetics, and the stromal code: Unraveling predictors of immune checkpoint blockade in renal cell carcinoma
Gabriel G. Malouf, IGBMC, Strasbourg, France
Short talks selected from proffered abstracts
BReak
10-10:30 a.m.
Plenary Session 2: Targeting Tumor Metabolism in Kidney Cancer
10:30 a.m.-12:30 p.m.
- 10:30 a.m.
M. Celeste Simon, Abramson Family Cancer Research Institute, Philadelphia, Pennsylvania - 11 a.m. | Computational strategies to interrogate kidney cancer metabolism
Ed Resnik, Memorial Sloan Kettering Cancer Center, New York, New York - 11:30 a.m. | Metabolic determinants of cancer metastasis
W. Kimryn Rathmell, The Ohio State University, Columbus, Ohio
Short talks selected from proffered abstracts
Lunch on Own / Free Time
12:30-2:30 p.m.
Plenary Session 3: New Paradigms on Kidney Cancer Treatments
2:30-4:30 p.m.
- 2:30 p.m.
Laurence Albiges, Gustave Roussy, Villejuif, France - 3 p.m.
Eric Jonasch, UT MD Anderson Cancer Center, Houston, Texas - 3:30 p.m. | Translating insights from the TME into novel therapies for kidney cancer
David F. McDermott, Beth Israel Deaconess Medical Center, Boston, Massachusetts
Short talks selected from proffered abstracts
Poster Session A / Reception
4:30-6:30 p.m.
Evening off / Dinner on Own
6:30 p.m.
Sunday, March 15
CONTINENTAL BREAKFAST
7-8 a.m.
Plenary Session 4 : Modeling Kidney Cancer
8-10 a.m.
- 8 a.m.
James Brugarolas, UT Southwestern Medical Center, Dallas, Texas - 8:30 a.m. | Modeling and modulating antitumor immunity in human cancer tissues
Daniela Thommen, Netherlands Cancer Institute, Amsterdam, Netherlands - 9 a.m. | Modeling rare kidney cancers: Elucidating pathogenesis and uncovering therapeutic vulnerabilities
Pavlos Msaouel, UT MD Anderson Cancer Center, Houston, Texas
Short talks selected from proffered abstracts
Break
10-10:30 a.m.
Plenary Session 5: Tumor Evolutions, Chromosomal Instability and Metastatic Tissue Tropism in Kidney Cancer
10:30 a.m.-12:30 p.m.
- 10:30 a.m.
Samra Turajlic, The Francis Crick Institute, London, United Kingdom - 11 a.m. | Integrated modeling of bone metastasis to dissect and overcome cancer therapy failure
Eleonora Dondossola, UT MD Anderson Cancer Center, Houston, Texas - 11:30 a.m.
Srinivas Malladi, University of Texas Southwestern Medical Center, Dallas, Texas
Short talks selected from proffered abstracts
Lunch on Own / Free Time
12:30-2:30 p.m.
Plenary Session 6: Advances on Studying Oncogenes and Tumor Suppressors in Kidney Cancer
2:30-4:30 p.m.
- 2:30 p.m. | The role of hypoxia pathways in kidney cancer
David Mole, University of Oxford, Oxford, United Kingdom - 3 p.m. | Therapeutic targeting of tumor suppressor signalings in ccRCC
Qing Zhang, UT Southwestern Medical Center, Dallas, Texas - 3:30 p.m. | Genetic approaches to target vulnerabilities in kidney cancer
James Nathan, University of Cambridge, Cambridge, United Kingdom - 4 p.m. | Chromophobe RCC: From pathogenesis to therapy
Elizabeth P. Henske, Harvard Medical School/Brigham and Women’s Hospital, Boston, Massachusetts
Poster Session B / Reception
4:30-6:30 p.m.
Evening off / Dinner on Own
6:30 p.m.
Monday, March 16
CONTINENTAL BREAKFAST
7-8 a.m.
Plenary Session 7: Subtypes of Kidney Cancer and Therapeutic Implications
8-10 a.m.
- 8 a.m. | Targeting protein phosphatase 5 to overcome drug resistance in ccRCC
Mehdi Mollapour, SUNY Upstate Medical University, Syracuse, New York - 8:30 a.m. | Targeting purine salvage dependence in FH-deficient kidney cancer
Heather R. Christofk, UCLA David Geffen School of Medicine, Los Angeles, California - 9 a.m. | From genomics to therapy: Mapping vulnerabilities in translocation renal cell carcinoma
Srinivas R. Viswanathan, Dana-Farber Cancer Institute, Boston, Massachusetts
Short talks selected from proffered abstracts
Break
10-10:30 a.m.
Plenary Session 8: Targeting Epigenetics in Kidney Cancer
10:30 a.m.-12:30 p.m.
- 10:30 a.m. | Nuclear speckles in ccRCC
Katherine Alexander, Cold Spring Harbor Laboratory, Cold Spring Harbor, New York - 11 a.m.
Cheryl L. Walker, Baylor College of Medicine, Houston, Texas - 11:30 a.m. | Transcriptional control of renal carcinogenesis
Sakari Vanharanta, University of Helsinki, Helsinki, Finland - 12 p.m. | PBRM1-deficient PBAF complexes target aberrant genomic loci to activate the NF-κB pathway in clear cell renal cell carcinoma
Bin T. Teh, National Cancer Centre Singapore, Singapore, Singapore
Closing Remarks
12:30 p.m.
- Eric Jonasch, UT MD Anderson Cancer Center, Houston, Texas
- M. Celeste Simon, Abramson Family Cancer Research Institute, Philadelphia, Pennsylvania
- Samra Turajlic, The Francis Crick Institute, London, England
- Qing Zhang, UT Southwestern Medical Center, Dallas, Texas